scholarly journals Yagya Therapy for Sub-Clinical Hypothyroidism: A Case Study

2018 ◽  
Vol 1 (2) ◽  
pp. 31-36 ◽  
Author(s):  
Shilpi Verma ◽  
Pawan Kumar ◽  
Alka Mishra ◽  
Vandana Shrivastava
Keyword(s):  
Thyroid Stimulating Hormone ◽  
Normal Range ◽  
Hormonal Balance ◽  
Effective Option ◽  
Low Levels ◽  
Traditional Approaches ◽  
In Fire ◽  
Very High ◽  
Tsh Levels

Sub-clinical hypothyroidism (SCH) is a condition in which Thyroid Stimulating Hormone (TSH) levels are increased, Thyroxine (T4) level is normal to low, and Triiodothyronine (T3) level is normal. Daily use of the synthetic thyroid hormone such as levothyroxine has been a standard approach to SCH. However, most modern approaches are unable to revert the condition to its normal level. Traditional approaches such as Yagya-Therapy can be an effective option in this regard. Yagya-Therapy provides pulmonary inhalation of medicinal-smoke of multiple herbs (generated through oblation in fire along with chanting of Vedic hymns), which have the potential for hormonal balance A case study is being reported wherein a patient (Male/60 years), who had been suffering from SCH since past 2 years and 4 months (pre-data), had been continuously taking allopathic medication for SCH, B12 complex and high blood pressure, and all this time TSH never became normal. The patient continued with the aforesaid medication, and took Yagya-Therapy for 3 months as an add-on therapy. Subsequently, after 4 months of completing Yagya-Therapy, post-data was recorded. Before Yagya-Therapy, TSH levels were very high, i.e. 4.79-11.82 µ/ml, which became normal (3.0 µ/ml) after the Yagya-Therapy. The earlier low levels of B12 (238-326 pg/ml) also increased to the upper side of the normal range (1034 pg/ml). Patient's other complaints such as tiredness, weakness, sleep issues were also resolved completely. Thus, the present study indicates the effectiveness of Yagya-Therapy in the treatment of SCH.

scholarly journals Comparison Study Between Local TSH IRMA Kit (CRRT) and Imported TSH IRMA Kit (Riakey, Korea)

2019 ◽  
Vol 4 (2) ◽  
pp. 77
Author(s):  
Gina Mondrida ◽  
Triningsih Triningsih ◽  
Kristina Dwi Purwanti ◽  
Sutari Sutari ◽  
Sri Setyowati ◽  
...  
Keyword(s):  
False Negative ◽  
Thyroid Stimulating Hormone ◽  
The Body ◽  
True Positive ◽  
Comparison Study ◽  
Complex Matrix ◽  
Normal Range ◽  
True Negative ◽  
Immunoassay Technique ◽  
Tsh Levels

<p><em>Thyroid Stimulating Hormone</em> (TSH) is one of hormones that our body need for growth of brains, bones and other tissues and regulate the metabolism in the body. Normal range of TSH for adult is from 0.3 to 5.5 µIU/ml, whereas for baby ranged from 3 to 18 µIU/ml. An Immunoradiometricassay (IRMA) is one of immunoassay technique using radionuclide as the tracer to detect low quantity of analyte. This technique is suitable for determine TSH levels in human blood serum which has complex matrix and various concentration. The Center for Radioisotope and Radiopharmaceutical Technology (CRRT)-BATAN has developed a reagent of TSH IRMA kit. The aim of this research is to compare between local TSH IRMA kit (CRRT-BATAN) and imported TSH IRMA kit (Riakey, Korea) toward 110 adult samples obtained from PTKMR - BATAN. The results showed 97 samples as true negative, 5 samples as true positive, 1 sample as false negative and 7 samples false positive. The comparison study gave diagnostic sensitivity as much as 83.33 %, diagnostic spesificity as much as 93.27 % and accuracy as much as 92.72 %.</p>

Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases

2011 ◽  
Vol 19 (4) ◽  
pp. 864-873 ◽  
Author(s):  
Jan Westerink ◽  
Yolanda van der Graaf ◽  
Daniël R Faber ◽  
Wilko Spiering ◽  
Frank LJ Visseren
Keyword(s):  
Myocardial Infarction ◽  
Vascular Disease ◽  
Vascular Diseases ◽  
Thyroid Stimulating Hormone ◽  
Tissue Thickness ◽  
Normal Range ◽  
Increased Risk ◽  
All Cause Mortality ◽  
Visceral Adipose ◽  
Tsh Levels

Aims: To investigate whether levels of thyroid-stimulating hormone (TSH) within the normal range are associated with an increased risk of new vascular events and mortality in patients with clinical manifest vascular diseases and whether this relation is influenced by adiposity. Methods and results: Prospective cohort study in 2443 patients (1790 men and 653 women) with clinical manifest vascular disease and TSH levels in the normal range. Median follow up was 2.7 (interquartile range 1.4–3.9) years. Clinical endpoints of interest were: myocardial infarction, stroke, vascular death, and all-cause mortality. In patients with manifest vascular disease, the prevalence of (subclinical) hypothyroidism was 5.7%, while 3.6% had (subclinical) hyperthyroidism. An increase in 1 unit of TSH was associated with a 33% higher risk (HR 1.33; 95% CI 1.03–1.73) for the occurrence of myocardial infarction, adjusted for age, gender, renal function, and smoking. In patients with a body mass index (BMI) below the median of 26.7 kg/m2 the HR per unit TSH for myocardial infarction was 1.55 (95% CI 1.08–2.21) compared to 1.18 (95% CI 0.81–1.71) in patients with a BMI ≥26.7 kg/m2. Visceral adipose tissue thickness below the median (≤8.8 cm) was associated with higher HR per unit TSH for myocardial infarction (HR 1.69; 95% CI 1.21–2.35) compared to visceral adipose tissue thickness >8.9 cm (HR 1.00; 95% CI 0.66–1.49). There was no relation between TSH and risk of stroke, vascular death, the combined endpoint, or all-cause mortality. Conclusion: Higher TSH levels within the normal range are associated with an increased risk of myocardial infarction, in patients with clinical manifest vascular disease. This relation is most prominent in patients without visceral obesity.

Is There Compensated Hypothyroidism in Infancy?

PEDIATRICS ◽  
1992 ◽  
Vol 90 (2) ◽  
pp. 207-211
Author(s):  
Ramin Alemzadeh ◽  
Silvia Friedman ◽  
Pavel Fort ◽  
Bridget Recker ◽  
Fima Lifshitz
Keyword(s):  
Screening Program ◽  
Thyroid Stimulating Hormone ◽  
Normal Serum ◽  
Close Monitoring ◽  
Normal Range ◽  
Thyroid Screening ◽  
Serum T4 ◽  
Hypometabolic State ◽  
Serum Tsh ◽  
Tsh Levels

The state-mandated newborn thyroid screening program may uncover infants who exhibit normal thyoxine (T4) levels with various degrees of hyperthyrotropinemia. To elucidate further the thyroid status, the basal metabolic rate (BMR) of 10 infants (7 boys, 3 girls; aged 9 to 63 days) was studied by indirect calorimetry. They were clinically euthyroid and healthy with no evidence of overt biochemical hypothyroidism (low T4, high thyroid-stimulating hormone [TSH]). Confirmatory testing indicated that all infants had normal serum T4 levels for age (mean ± SD: 10.3 ± 3.2 µg/dL). However, serum TSH levels varied from 2.3 to 99.2 µU/mL In 4 infants (2 boys, 2 girls) the BMR was low (38.1 ± 4.1 kcal/kg per day), while the other 6 patients (5 boys, 1 girl) demonstrated BMRs within the normal range (49.6 ± 1.9 kcal/kg per day, P &lt; .001). The serum TSH levels were above 7.0 µU/mL among those infants with a low BMR, whereas the serum TSH levels were always below 6.0 µU/mL among the normometabolic infants. All infants who had a low BMR received thyroid therapy and promptly became normometabolic (BMR: 48.7 ± 1.0 kcal/kg per day) with suppression of TSH levels (3.2 ± 1.3 µU/mL) within 3 weeks of therapy, while their serum T4 levels remained within the normal range. The observed normalization of BMR In parallel to reduction of TSH levels following thyroid replacement therapy strongly suggests that these patients demonstrated a hypometabolic state, despite normal serum T4 levels. Therefore, the assessment of BMR may help define subclinical hypothyroidism in infancy in conjunction with a close monitoring of TSH concentration.

P1536Does free thyroxine (fT4) predict risk of atherosclerotic cardiovascular disease (ASCVD)?

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
J L Anderson ◽  
V Jacobs ◽  
H T May ◽  
T L Bair ◽  
B A Benowitz ◽  
...  
Keyword(s):  
Thyroid Stimulating Hormone ◽  
Atherosclerotic Cardiovascular Disease ◽  
Reference Ranges ◽  
Rotterdam Study ◽  
Normal Range ◽  
Hormone Levels ◽  
Prevalent Disease ◽  
Artery Disease ◽  
Intermountain Healthcare ◽  
Tsh Levels

Abstract Background Thyroid hormones are associated with arrhythmic risk, but their relationship to ASCVD is unclear. The Rotterdam Study* reported associations of higher fT4 and lower thyroid stimulating hormone (TSH) levels with ASCVD, including within the euthyroid range. Free T3 (fT3) was not assessed. Methods We tested whether fT4, fT3, and TSH levels were associated with ASCVD in Intermountain Healthcare. All patients >18 y old with an fT4 level in the electronic medical record database were included. The hormone reference ranges were divided into quartiles (Q), and associations with prevalent and incident ASCVD were assessed by multivariable regression and trend tests. Results A total of 212,202 patients (age = 64.4±11.2 y; 66.6% women) were included and followed for 6.1±4.4 y. Of these, 8.3%, 86.6%, and 5.1% had fT4 levels below, within, and above the reference range. CAD was prevalent in 18.9% of fT4 Q1 patients. The adjusted odds ratio (OR) for coronary artery disease (CAD) increased through (Q4/Q1 OR=1.36) and beyond (High/Q1 OR=1.71) the normal range, p-trend<0.001 (Table). Smaller incremental risks were noted for fT3 (Q4/Q1 OR=1.13; High/Q1 OR=1.25). The frequencies of incident MI (Q1=2.5%) and stroke (Q1=5.4%) were low and did not show a concentration-related risk gradient. Incident all-cause death (Q1=24.3%) increased slightly for Q4 and high fT4 (OR=1.05, 1.06) but not fT3; death also increased with low fT4 (OR=1.28). TSH showed no consistent gradient within the normal range for prevalent or incident events; however, mortality increased with both high and low TSH. Thyroid Hormone Levels and Prevalent CAD Prevalent CAD (adjusted OR) Low Normal Q1 Normal Q2 Normal Q3 Normal Q4 High fT4 (n=212,202) OR=1.08, p=0.02 OR=1.00 referent OR=1.11, p<0.001 OR=1.21, p<0.001 OR=1.36, p<0.001 OR=1.71, p<0.001 fT3 (n=30,200) OR=1.12, p<0.001 OR=1.00 referent OR=0.98, p=0.61 OR=1.02, p=0.53 OR=1.13, p<0.001 OR=1.25, p<0.001 TSH (n=183,227) OR=1.39, p<0.001 OR=1.00 referent OR=0.93, p=0.42 OR=0.88, p=0.15 OR=0.92, p=0.35 OR=1.73, p<0.001 Reference Q 1–4 are: fT4: 0.75–0.90; 0.91–1.01; 2.02–1.14; 1.15–1.50 ng/dL; TSH: 0.54–1.30; 1.31–2.04; 2.05–3.68; 3.69–6.80 uIU/mL; fT3: 2.40–2.60; 2.70–2.80; 2.90–3.10; 3.20–4.20 pg/dL. Conclusions Consistent with the Rotterdam Study, we found an increase in prevalent CAD with increasing fT4 levels within and beyond the normal range and, uniquely, a more modest relationship with fT3. We could not confirm a normal-range relationship between hormone levels and incident events or between TSH and prevalent disease. The relationship of fT4 levels to ASCVD is intriguing, is deserving of further study, and may have important implications for ASCVD prevention. *A Bano, et-al. Circ Res 2017; 121:1397–1400

scholarly journals Preoperative thyroid-stimulating hormone associated risk of differentiated thyroid cancer in patients with thyroid nodules

2021 ◽  
Vol 67 (3) ◽  
pp. 85-91
Author(s):  
Al Essa M
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Thyroid Nodules ◽  
Conditional Logistic Regression ◽  
Care Center ◽  
Tertiary Care ◽  
Thyroid Stimulating Hormone ◽  
Normal Range ◽  
Tsh Levels ◽  
Stimulating Hormone

In an assessment of risk for differentiated thyroid cancer (DTC) in individuals with human papillary thyroid cancer (PTC) and thyroid nodules a cohort prospective study was undertaken to establish the significance of preoperative thyroid-stimulating hormone (TSH) levels. Confirmed histologically PTC cases in one tertiary care center, and matched healthy individuals were tested for TSH, T3, T4 and T4 free total. The ORs and 95% confidence intervals have been calculated using conditional logistic regression models (CI). The blood TSH levels were related to the higher risk of PTC for men (OR,0,09; 95% Ci, 04–0,21, 95% CI and women) compared with the middle tertile of the TSH levels in the normal range (OR,0,07; 95 percent CI, 0,04–0,1). Over the normal range of TSH levels, an elevated PTC risks were connected amongst women (OR 0,09; 95% CI, 0,04–0,21) but not amongst men (OR,0,07; 95% CI, 0,04–0,1). With an increase in TSH level in the normal range between men and women, the risk for PTC reduced (Ptrend=0.041 and 0.0001). The risk of PTC related to TSH levels has been dramatically elevated above  the normal range for men  and TSH values below the normal range for women.

A rare cause of subclinical hypothyroidism: macro-thyroid-stimulating hormone

Diagnosis ◽  
2020 ◽  
Vol 7 (1) ◽  
pp. 75-77
Author(s):  
Cem Onur Kirac ◽  
Sedat Abusoglu ◽  
Esra Paydas Hataysal ◽  
Aysegul Kebapcilar ◽  
Suleyman Hilmi Ipekci ◽  
...  
Keyword(s):  
Subclinical Hypothyroidism ◽  
Thyroid Stimulating Hormone ◽  
Overt Hypothyroidism ◽  
Normal Range ◽  
Free Triiodothyronine ◽  
Case Presentation ◽  
Chronic Autoimmune Thyroiditis ◽  
Levothyroxine Replacement ◽  
Tsh Levels ◽  
Stimulating Hormone

AbstractBackgroundSubclinical hypothyroidism is a situation in which the thyroid-stimulating hormone (TSH) value exceeds the upper limit of normal, but the free triiodothyronine (T3) and thyroxine (T4) values are within the normal range. The etiology is similar to overt hypothyroidism.Case presentationAn 18-year-old female patient was referred to our endocrinology clinic due to elevated TSH levels detected during a routine examination. She was clinically euthyroid and had a normal thyroid ultrasound pattern. The TSH concentration was measured twice independently, giving values of 5.65 μIU/mL and 5.47 μIU/mL. The polyethylene glycol (PEG) method for TSH measurement was used to determine the concentration of macro-TSH (m-TSH), a macromolecule formed between TSH and immunoglobulin (Ig). Using the same blood samples for which the TSH levels were found to be high, the PEG method found TSH levels to be within a normal range, with values of 1.50 μIU/mL (5.65–1.50 μIU/mL measured; a decrease of 75%) and 1.26 μIU/mL (5.47–1.26 μIU/mL measured; a decrease of 77%), respectively. The TSH values determined by the PEG precipitation test were markedly low, with PEG-precipitable TSH ratios greater than 75%.ConclusionsThe cause of 55% of subclinical hypothyroidism is chronic autoimmune thyroiditis. However, it is necessary to exclude other TSH-elevated conditions for diagnosis. One of these conditions is m-TSH, which should be kept in mind even though it is rarely seen. m-TSH should be considered especially in patients who have a TSH value above 10 μIU/mL without hypothyroidism symptoms or who require a higher levothyroxine replacement dose than expected to make them euthyroid.

scholarly journals Observational study on association between serum thyroid stimulating hormone and thyroid malignancy

2017 ◽  
Vol 4 (6) ◽  
pp. 2002
Author(s):  
Arun K. ◽  
Santhosh Nayak K. ◽  
Suhas Gowda
Keyword(s):  
Thyroid Cancer ◽  
Observational Study ◽  
Thyroid Nodules ◽  
Thyroid Stimulating Hormone ◽  
Normal Range ◽  
Advanced Stages ◽  
Test Of Significance ◽  
Serum Tsh ◽  
Tsh Levels ◽  
Stimulating Hormone

Background: Thyroid cancer is the most common endocrine malignancy and its incidence continues to rise. Thyroid carcinoma in most cases presents clinically as a solitary nodule or as a dominant nodule within a multinodular thyroid gland. There are a number of well-established of predictors of malignancy in thyroid nodules. More recently studies have suggested that higher concentration of TSH, even within the normal range are associated with subsequent diagnosis of thyroid cancer in patients with thyroid nodules and even higher serum TSH levels have been found associated with advanced stages of thyroid cancer. Objectives were to determine the association between serum thyroid stimulating hormone (TSH) concentration and thyroid cancer and to estimate serum TSH levels in different stages of thyroid malignancy.Methods: A hospital based observational study was conducted in a tertiary care hospital for a period of 2 year. 120 patients presenting with thyroid nodule without an overt thyroid dysfunction during the study period were included in the study. Chi-square was used as test of significance. Independent t test was the test of significance for quantitative data between two groups.Results: In the study majority of thyroid cancer patients (106 out of 120) had serum TSH concentrations ranging 1.71mIU/L-5.5mIU/L i.e. within normal range but towards higher range. Mean serum TSH concentrations was significantly high in advanced stages of carcinoma. Mean Serum TSH was high in Stage III and Stage IV (5.17±1.36mIU/l) compared to stage I and II (4.03±1.87mIU/l).Conclusions: The study concludes that TSH levels were in the Upper reference range in majority of thyroid malignancies and high levels of serum TSH concentrations associated with advanced stage of thyroid cancer.

scholarly journals Distribution of Myeloid and Plasmacytoid Dendritic Cell Subpopulations in Peripheral Blood of Hyperprolactinemic Women

2021 ◽  
Author(s):  
Fatemeh Raeesi Nejad ◽  
Mohammad Mahdi Mohammadi ◽  
Mojgan Sanjari ◽  
Reza Malkpour Afshar ◽  
Elham Jafari
Keyword(s):  
Peripheral Blood ◽  
Plasmacytoid Dendritic Cell ◽  
Serum Levels ◽  
Thyroid Stimulating Hormone ◽  
Healthy Controls ◽  
Normal Range ◽  
Normal Thyroid Function ◽  
Neuroendocrine Axis ◽  
And Function ◽  
Tsh Levels

Dendritic cells (DCs) play key roles in regulating the immune response using the specialized function of processing and presenting antigens. Prolactin (PRL), a hormone produced by the pituitary gland, participates in DC maturation and function. The present study was aimed to determine the frequencies of peripheral blood DC subpopulations of myeloid DC (MDC) and plasmacytoid DC (PDC) in hyperprolactinemic (HPRL) women compared to normal healthy volunteers. This study was conducted on 70 women, including 35 HPRL patients and 35 matched healthy controls, whose PRL serum levels were in the normal range (lower than 25 ng/mL). Serum thyroid-stimulating hormone (TSH) levels were measured in both groups as an indicator of normal thyroid function. The electrochemiluminescence immunoassay method was applied to measure the serum levels of TSH and PRL. The frequencies of MDC and PDC in the peripheral blood samples of both groups were determined by flow cytometry. The mean serum PRL levels in the HPRL patients and healthy individuals were 46.41±21.96 and 13.75±11.19, respectively (p<0.0001); however TSH levels in both groups were similar and within the normal range (0.4–4.5 mIU/mL) (p=0.2). The frequencies of both MDC and PDC subpopulations in the peripheral blood of HPRL patients were significantly lower than they were in the healthy controls. However, the ratio of MDCs/PDCs in HPRL patients was not significantly different between the two groups (p=0.8). Our study revealed that an increased level of serum PRL may lead to a reduction in the number of MDC and PDC subpopulations. These results could help clarify the complex relationship between the immune system and the neuroendocrine axis and may be of potential use in understanding the pathogenesis of endocrine and immune disorders.

Genetics and clinical significance of thyroxine binding globulin deficiency, an analysis of seven families

1985 ◽  
Vol 109 (1) ◽  
pp. 83-89
Author(s):  
M. Kollind ◽  
L. Iselius ◽  
T. Pettersson ◽  
U. Adamson ◽  
A. Carlström
Keyword(s):  
Clinical Symptoms ◽  
Thyroid Stimulating Hormone ◽  
Blood Levels ◽  
Normal Range ◽  
Mothers And Daughters ◽  
Nuclear Families ◽  
Thyroxine Binding Globulin ◽  
Mode Of Transmission ◽  
Points Of View ◽  
Tsh Levels

Abstract. Seven families, ascertained through probands with undetectable levels of thyroxine binding globulin (TBG) were studied from clinical and genetic points of view. The blood levels of TBG, thyroxine binding prealbumin (TBPA), thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) were determined in altogether 128 family members. The concentration of free thyroxine (FT4) was calculated from the concentrations of T4, TBG and TBPA. Only men (n = 15) were found to have total TBG deficiency. Their TSH levels were within normal range and they did not show any clinical symptoms of thyroid dysfunction. The mothers and daughters of the affected men had significantly lower TBG levels than control women. Segregation analysis performed on 46 nuclear families showed significant evidence for an X-linked additive mode of transmission and an additional multifactorial component with heritability 0.47.

Thrombotic Thrombocytopenic Purpura: Mechanism for Effectiveness of Plasmapheresis

1979 ◽  
Author(s):  
J. G. Kelton ◽  
P. B. Neame ◽  
I. Walker ◽  
A. G. Turpie ◽  
J. McBride ◽  
...  
Keyword(s):  
Platelet Count ◽  
Thrombotic Thrombocytopenic Purpura ◽  
The Other ◽  
Unknown Etiology ◽  
Normal Range ◽  
Antiplatelet Antibody ◽  
Thrombocytopenic Purpura ◽  
Serious Illness ◽  
Normal Platelet ◽  
Very High

Thrombotic thrombocytopenic purpura (TTP) is a rare but serious illness of unknown etiology. Treatment by plasmapheresis has been reported to be effective but the mechanism for benefit is unknown. We have investigated the effect of plasmapheresis in 2 patients with TTP by quantitating platelet associated IgG (PAIgG) levels prior to and following plasmapheresis. Both patients had very high levels of PAIgG at presentation (90 and A8 fg IgG/platelet respectively, normal 0-5). in both, the PAIgG levels progressively fell to within the normal range and the platelet count rose following plasmapheresis. One patient remained in remission with normal platelet counts and PAIgG levels. The other relapsed after plasmapheresis and the PAIgG level rose prior to the fall in platelet count. Plasmapheresis was repeated and resulted in normalization of both the platelet count and PAIgG level. It is suggested that plasmapheresis removes antiplatelet antibody or immune complexes which may be of etiological importance in this illness.

Sign in / Sign up

Export Citation Format

Share Document